S
26.97
2.71 (11.17%)
| 前收盘价格 | 24.26 |
| 收盘价格 | 24.95 |
| 成交量 | 912,989 |
| 平均成交量 (3个月) | 846,525 |
| 市值 | 2,092,659,584 |
| 价格/销量 (P/S) | 650.22 |
| 股市价格/股市净资产 (P/B) | 8.29 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2025 |
| 稀释每股收益 (EPS TTM) | -3.06 |
| 总债务/股东权益 (D/E MRQ) | 0.06% |
| 流动比率 (MRQ) | 8.06 |
| 营业现金流 (OCF TTM) | -169.86 M |
| 杠杆自由现金流 (LFCF TTM) | -68.57 M |
| 资产报酬率 (ROA TTM) | -25.34% |
| 股东权益报酬率 (ROE TTM) | -65.82% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Spyre Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.1
| 分析师共识 | 5.0 |
| 内部交易活动 | 3.0 |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.10 |
|
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 8.71% |
| 机构持股比例 | 106.07% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 70.00 (BTIG, 159.55%) | 购买 |
| 中 | 64.00 (137.30%) | |
| 低 | 53.00 (Mizuho, 96.52%) | 购买 |
| 平均值 | 62.75 (132.67%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 32.11 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| BTIG | 16 Jan 2026 | 70.00 (159.55%) | 购买 | 33.24 |
| Mizuho | 18 Dec 2025 | 53.00 (96.51%) | 购买 | 33.47 |
| Citigroup | 17 Dec 2025 | 64.00 (137.30%) | 购买 | 33.06 |
| Jones Trading | 01 Dec 2025 | 64.00 (137.30%) | 购买 | 28.66 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 23 Jan 2026 | 公告 | Spyre Therapeutics Announces Grants of Inducement Awards |
| 12 Jan 2026 | 公告 | Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 |
| 08 Jan 2026 | 公告 | Spyre Therapeutics Announces Grants of Inducement Awards |
| 05 Dec 2025 | 公告 | Spyre Therapeutics Announces Grants of Inducement Awards |
| 07 Nov 2025 | 公告 | Spyre Therapeutics Announces Grants of Inducement Awards |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合